Pancreatic Cancer Research

ResearcherSir Run Run Shaw HospitalActive in the last 2 years

Yunyun Xu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-6371-054X; OpenAlex author ID A5068676227. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
25
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 8

  1. Discovery of compound 1105486 as a selective inhibitor of B4GALT1: potential for pancreatic cancer therapy. Co-author DOI 10.3389/fchem.2025.1651402↗
  2. Screening, optimization, and ADMET evaluation of HCJ007 for pancreatic cancer treatment through active learning and dynamics simulation. Co-author DOI 10.3389/fchem.2024.1482758↗
  3. Factors predicting recurrence after left‑sided pancreatectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12957-023-03080-z↗
  4. B7H6 Serves as a Negative Prognostic Marker and an Immune Modulator in Human Pancreatic Cancer. Co-author DOI 10.3389/fonc.2022.814312↗
  5. A Neoantigen-Based Peptide Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment. Co-author DOI 10.3389/fimmu.2021.691605↗
  6. A Peptide-Based Neoantigen Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard Treatment Co-author DOI 10.21203/rs.3.rs-130888/v1↗
  7. Conversion Therapy for Advanced Pancreatic Cancer: The Case Series and Literature Review. First author DOI 10.3389/fphar.2020.579239↗
  8. Snail contributes to the maintenance of stem cell-like phenotype cells in human pancreatic cancer. Co-author DOI 10.1371/journal.pone.0087409↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mou Yiping · 1 shared paper, 2025 · strength 0.54
  2. Yiping Mou · 3 shared papers, 2014–2024 · strength 0.50
  3. Zheling Chen · 3 shared papers, 2020–2021 · strength 0.32
  4. Jiahong Jiang · 3 shared papers, 2020–2021 · strength 0.32
  5. Yuanyu Wang · 1 shared paper, 2023 · strength 0.17
  6. Peng Xu · 1 shared paper, 2023 · strength 0.17
  7. Yucheng Zhou · 1 shared paper, 2023 · strength 0.17
  8. Tao Xia · 1 shared paper, 2023 · strength 0.17
  9. Weiwei Jin · 1 shared paper, 2023 · strength 0.17
  10. Liu Yang · 1 shared paper, 2021 · strength 0.11
  11. Mingxing Wang · 1 shared paper, 2020 · strength 0.11
  12. Dongsheng Huang · 1 shared paper, 2020 · strength 0.11
  13. Dechun Li · 1 shared paper, 2022 · strength 0.11
  14. Xin Zhao · 1 shared paper, 2022 · strength 0.11
  15. Jianhua Yu · 1 shared paper, 2022 · strength 0.11
  16. Kun‐Yu Teng · 1 shared paper, 2022 · strength 0.11
  17. Songbing He · 1 shared paper, 2022 · strength 0.11
  18. Zheng Gang Zhu · 1 shared paper, 2022 · strength 0.11
  19. Zhenyu Dai · 1 shared paper, 2022 · strength 0.11
  20. Vincent M. Chung · 1 shared paper, 2022 · strength 0.11
  21. Jian Zhou · 1 shared paper, 2022 · strength 0.11
  22. Liang Liu · 1 shared paper, 2020 · strength 0.09
  23. Liu Yang · 1 shared paper, 2020 · strength 0.09
  24. Liewei Wang · 1 shared paper, 2014 · strength 0.04
  25. Wei Zhou · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.